Our top pick for
Schrödinger Inc is a health information services business based in the US. Schrödinger shares (SDGR) are listed on the NASDAQ and all prices are listed in US Dollars. Schrödinger employs 445 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$52.67|
|52-week range||$47.59 - $117.00|
|50-day moving average||$57.98|
|200-day moving average||$67.06|
|Wall St. target price||$87.60|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.61|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-4.86%|
|1 month (2021-09-24)||-9.11%|
|3 months (2021-07-23)||-24.63%|
|6 months (2021-04-23)||-30.40%|
|1 year (2020-10-23)||-13.10%|
|2 years (2019-10-20)||N/A|
|3 years (2018-10-20)||N/A|
|5 years (2016-10-20)||N/A|
|Revenue TTM||$120.7 million|
|Gross profit TTM||$63.5 million|
|Return on assets TTM||-10.11%|
|Return on equity TTM||-9.71%|
|Market capitalisation||$3.9 billion|
TTM: trailing 12 months
There are currently 4.5 million Schrödinger shares held short by investors – that's known as Schrödinger's "short interest". This figure is 6.5% down from 4.8 million last month.
There are a few different ways that this level of interest in shorting Schrödinger shares can be evaluated.
Schrödinger's "short interest ratio" (SIR) is the quantity of Schrödinger shares currently shorted divided by the average quantity of Schrödinger shares traded daily (recently around 553233.16770186). Schrödinger's SIR currently stands at 8.05. In other words for every 100,000 Schrödinger shares traded daily on the market, roughly 8050 shares are currently held short.
However Schrödinger's short interest can also be evaluated against the total number of Schrödinger shares, or, against the total number of tradable Schrödinger shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Schrödinger's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Schrödinger shares in existence, roughly 60 shares are currently held short) or 0.083% of the tradable shares (for every 100,000 tradable Schrödinger shares, roughly 83 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Schrödinger.
Find out more about how you can short Schrödinger stock.
We're not expecting Schrödinger to pay a dividend over the next 12 months.
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.